MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial

被引:7
|
作者
Gormly, Kirsten L. [1 ]
Coscia, Claudio [1 ]
Wells, Tim [1 ]
Tebbutt, Niall [2 ]
Harvey, Jennifer A. [3 ]
Wilson, Kate [4 ]
Schmoll, Hans-Joachim [5 ]
Price, Timothy [6 ,7 ]
机构
[1] Dr Jones & Partners Med Imaging, Adelaide, SA, Australia
[2] Austin Hlth, Olivia Newton John Canc & Wellness Ctr, Melbourne, Vic, Australia
[3] Princess Alexandra Hosp, Brisbane, Qld, Australia
[4] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[5] Martin Luther Univ Halle Wittenberg, Halle, Germany
[6] Univ Adelaide, Queen Elizabeth Hosp, Adelaide, SA, Australia
[7] AGITG, Adelaide, SA, Australia
关键词
audit; MRI; rectal cancer; RESECTION MARGIN; ACCURACY; MANAGEMENT;
D O I
10.1111/1754-9485.12493
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: An MRI audit substudy was conducted in patients who underwent an MRI prior to treatment in Australia and New Zealand as part of the PETACC-6 trial in locally advanced rectal cancer. Methods: A total of 82 patients from 15 centres had rectal MRI scans reviewed for technique, data included in reports and comparison of reports with blinded central reporting by two experienced radiologists. Results: In total, 82% performed minimum T2 sagittal and T2 axial oblique sequences. The high-resolution T2 sequence parameters varied significantly with only 33% obtaining a voxel size of <1.3 mm(3). The rate of inclusion of relevant findings in the reports was T3 distance in mm 21%, N stage 84%, circumferential resection margin ( CRM) status 72%, extramural venous invasion ( EMVI) status 29% and distance from the puborectalis sling 17%. In total, 31% reports included all of T stage with T3 substage, N stage and CRM involvement. In total, 17% reports included these 3 findings and EMVI. Eleven reports used a template with 82% of these including the first 3 findings. The agreement with central reporters was T stage 76%, N stage 70%, CRM status 57% and EMVI 16%. Conclusion: There is significant variation in scan quality and low rates of including all relevant findings in rectal MRI reports in the audit. The authors recommend adoption of routine sequences and template reports in both trial settings and routine practice to improve scan technique and adequacy of reports in rectal cancer MRI staging scans across Australia and New Zealand.
引用
收藏
页码:607 / 615
页数:9
相关论文
共 50 条
  • [41] Data quality of the Australia and New Zealand Dialysis and Transplant Registry: A pilot audit
    Gray, Nicholas A.
    Mahadevan, Kumar
    Campbell, Victoria K.
    Noble, Euan P.
    Anstey, Chris M.
    NEPHROLOGY, 2013, 18 (10) : 665 - 670
  • [42] Protocol for a national audit of the watch-and-wait approach in patients with rectal cancer in Aotearoa New Zealand: The ACCORD study
    Mcguinness, Matthew James
    Xu, William
    Wells, Cameron
    Varghese, Chris
    Elliott, Brodie
    Edwards, Melissa
    Paterson, Luke
    Collins, Ray
    Bissett, Ian P.
    Windsor, John A.
    Panaho, Joy
    Wright, Deborah
    Harmston, Christopher
    COLORECTAL DISEASE, 2024, 26 (02) : 371 - 379
  • [43] Rectal Cancer Treatment Outside of the Screening Age in Australia and New Zealand: An Analysis of the Bi-National Colorectal Cancer Audit (BCCA) (vol 46, pg e106, 2020)
    Van Harten, Meike
    Greenwood, Emma
    Bedrikovetski, Sergei
    Dudi-Venkata, Nagendra
    Hunter, Ronald
    Kroon, Hidde
    Sammour, Tarik
    EJSO, 2020, 46 (06): : 1200 - 1200
  • [44] PET/MRI and PET/CT hybrid imaging of rectal cancer - description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study
    Rutegard, Miriam K.
    Batsman, Malin
    Axelsson, Jan
    Brynolfsson, Patrik
    Brannstrom, Fredrik
    Rutegard, Jorgen
    Ljuslinder, Ingrid
    Blomqvist, Lennart
    Palmqvist, Richard
    Rutegard, Martin
    Riklund, Katrine
    CANCER IMAGING, 2019, 19 (1):
  • [45] Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
    Schmoll, Hans-Joachim
    Stein, Alexander
    Van Cutsem, Eric
    Price, Timothy
    Hofheinz, Ralf D.
    Nordlinger, Bernard
    Daisne, Jean-Francois
    Janssens, Jos
    Brenner, Baruch
    Reinel, Hans
    Hollerbach, Stephan
    Caca, Karel
    Fauth, Florian
    Hannig, Carla V.
    Zalcberg, John
    Tebbutt, Niall
    Mauer, Murielle E.
    Marreaud, Sandrine
    Lutz, Manfred P.
    Haustermans, Karin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (01) : 17 - +
  • [46] Sentinel node biopsy in breast cancer - the view from Australia and New Zealand
    Kollias, J
    Gill, PG
    BREAST, 2001, 10 (04): : 285 - 286
  • [47] PET/MRI and PET/CT hybrid imaging of rectal cancer – description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study
    Miriam K. Rutegård
    Malin Båtsman
    Jan Axelsson
    Patrik Brynolfsson
    Fredrik Brännström
    Jörgen Rutegård
    Ingrid Ljuslinder
    Lennart Blomqvist
    Richard Palmqvist
    Martin Rutegård
    Katrine Riklund
    Cancer Imaging, 19
  • [48] Surgical outcomes following colorectal cancer resections in patients aged 80 years and over: results from the Australia and New Zealand Binational Colorectal Cancer Audit
    Cross, Andrea J.
    Kornfalt, Pauline
    Lidin, Jacqueline
    Buchwald, Pamela
    Frizelle, Frank A.
    Eglinton, Timothy W.
    COLORECTAL DISEASE, 2021, 23 (04) : 814 - 822
  • [49] The IDEAL trial in Australia and New Zealand: clinical and economic impact
    Dansie, Kathryn B.
    Davies, Christopher E.
    Morton, Rachael L.
    Hawley, Carmel M.
    Johnson, David W.
    Craig, Jonathan C.
    Chapman, Jeremy R.
    Cooper, Bruce A.
    Pollock, Carol A.
    Harris, David C. H.
    McDonald, Stephen P.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (01) : 168 - 174
  • [50] Comparison of cancer mortality and incidence in New Zealand and Australia
    Skegg, DCG
    McCredie, MR
    NEW ZEALAND MEDICAL JOURNAL, 2002, 115 (1153) : 205 - 208